Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
endocrine system diseases | D004700 |
Brand Name | Status | Last Update |
---|---|---|
thyrogen | Biologic Licensing Application | 2023-02-24 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
thyroid neoplasms | EFO_0003841 | D013964 | — |
Expiration | Code | ||
---|---|---|---|
thyrotropin alfa, Thyrogen, Genzyme Corporation | |||
2114-12-14 | Orphan excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 1 | 2 | — | 2 | 5 |
Thyroid diseases | D013959 | — | E00-E07 | — | 1 | 2 | — | 2 | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Goiter | D006042 | EFO_0004283 | E04.9 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Thyrotropin alfa |
INN | thyrotropin alfa |
Description | Thyrogen (thyrotropin alfa) is a protein pharmaceutical. Thyrotropin alfa was first approved as Thyrogen on 2000-03-09. It is used to treat thyroid neoplasms in the USA. It has been approved in Europe to treat thyroid neoplasms. The pharmaceutical is active against thyrotropin receptor. |
Classification | Protein |
Drug class | tricyclic compounds; atropine derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201533 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | AVX3D5A4LM (ChemIDplus, GSRS) |